Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Trends in the global immuno-oncology landscape

An Erratum to this article was published on 26 October 2018

This article has been updated

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Trends in the global IO pipeline.
Figure 2: Trends in IO targets.
Figure 3: Trends in organizations with IO agents in clinical development.

Change history

  • 26 October 2018

    In the original version of Figure 1, the label on the y axis 'T cell-targeted' was incorrect and should be 'T cell-targeted immunomodulator'. The article has been corrected in the online version.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Jun Tang.

Ethics declarations

Competing interests

J.O-T. is a paid board member of HemaCare. L. P. is a consultant to Cancer Research Institute and Canadian Cancer Trials Group.

Related links

PowerPoint slides

Supplementary information

Supplementary information

Supplementary Table (XLSX 23 kb)

Supplementary information

Trends of TAA-targeted IO agents in the past year. (PDF 183 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, J., Pearce, L., O'Donnell-Tormey, J. et al. Trends in the global immuno-oncology landscape. Nat Rev Drug Discov 17, 783–784 (2018).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research